Market News / Story
Alumis Inc. (ALMS) Reports New Phase 3 Psoriasis Data; NDA Planned for 4Q 2026
·
Alumis reported new ONWARD Phase 3 data showing envudeucitinib improved scalp disease, itch, and QoL, with ONWARD3 showing 54% PASI 100 at Week 48. The company remains on track to submit an NDA for moderate-to-severe plaque psoriasis in 4Q 2026. Material Details #DetailAI Analyst View154% PASI 100 at Week 48High complete clearance rate strengthens efficacy case vs. oral peers.2Rapid responses after switchPatients switching from placebo/apremilast caught up by Week 48,…